Navigation Links
Derma Sciences Announces Multiple Clinical Posters Featuring MEDIHONEY(R) and ALGICELL Ag(R) to be Presented at Upcoming Wound Care Conference

Clinical evidence continues to build for the company's key technologies

PRINCETON, N.J., Oct. 22 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTC Bulletin Board: DSCI), a company specializing in advanced wound care, today announced that eleven clinical posters focusing on its new technologies have been accepted and will be presented at next week's Clinical Symposium on Advances in Skin & Wound Care in Las Vegas. The products featured include MEDIHONEY dressing with Active Leptospermum Honey, ALGICELL Ag Silver Antimicrobial dressing, and XTRASORB(TM) Super Absorbent dressing. The clinical posters review cases of hard-to-heal wounds of various etiologies, and depict how Derma Sciences' new technologies are helping to improve care for the elderly, patients with diabetes and vascular diseases, and immuno-compromised patients. This patient population, exceeding 70 million worldwide, sees great quality of life improvements when chronic wounds are healed faster and with fewer complications, and when infections are either prevented or cleared more quickly.

Clinical posters at wound conferences typically focus on cases involving difficult-to-heal wounds, and relate a clinician's perspective on how a given technology or methodology helped in the management of the condition. The posters are initially submitted as abstracts and are peer reviewed. If the abstract is accepted, a large poster showing before and after pictures of the case series -- along with detailed explanations as to the issues, rationales, methodologies, outcomes, and conclusions -- is created and is presented to the conference attendees as a part of the overall continuing education program. Four of the most recently completed and not previously announced posters featuring Derma Sciences' products include:

"Limb at Risk: Use of Active Leptospermum Honey for the management of an infected foot wound complicated by cellulitis." (MEDIHONEY(R))

Paul A. Ligouri, MD, Kim L. Peters, RN, CWS

Whittier Rehabilitation Hospital, Bradford, MA

"Active Leptospermum Honey: Treatment for various lower extremity dermatologic issues." (MEDIHONEY(R))

Tracey C. Vlahovic, DPM, associate professor, Eric Roberts, BS

Temple University School of Podiatric Medicine, Philadelphia, PA

"Management of an MRSA colonized wound using Active Leptospermum Honey impregnated calcium alginate." (MEDIHONEY(R) & XTRASORB(TM))

Mary Webb, RN, BSN, MA, CIC, Infection Control Practitioner

San Mateo Medical Center, San Mateo, CA

"A cost-effective alternative: Investigating absorbent gelling calcium alginate dressings with antimicrobial silver." (ALGICELL Ag(R))

Connie Johnson, RN, WCC, Care One, Madison, New Jersey

With regard to the clinical presentations at the Clinical Symposium, CEO Ed Quilty stated, "The interest in our products, led by MEDIHONEY(R), continues to increase. Given that advancing wound care is our stated goal, it is rewarding to see that eleven clinical posters on our products have been accepted for presentation at this highly regarded conference. The posters on MEDIHONEY do an excellent job showing the variety of wounds that can be managed with this versatile dressing. The poster on XTRASORB goes right to the heart of the issue with this dressing -- a patient was able to be discharged from the hospital due to his ability to easily change this super absorbent dressing at home. Previously, dressing changes were multiple times per day and required nursing assistance. We believe this dressing is going to help facilities save a great deal of money due to its benefits over conventional absorbent dressings. Lastly, as our sales of MEDIHONEY have increased, so have our sales of ALGICELL Ag. Connie Johnson's poster is a perfect example of how this cost-effective alternative enables clinicians to save money while maintaining a highly effective dressing regimen."

Quilty concluded, "As planned, our products are having a meaningful difference on the lives of patients with chronic and hard-to-heal wounds. The evidence supporting our new technologies is growing, as is our reputation in the field of advanced wound care."

The Clinical Symposium on Advances in Skin & Wound Care is an annual conference, held this year October 26-30, 2008, in Las Vegas. The goal of the 23rd annual event is to meet the continuing-education needs of multidisciplinary skin and wound care practitioners, from novice to expert, by providing a forum for educational sessions and interactive workshops that offer comprehensive wound management strategies. Over 1,100 multidisciplinary practitioners including nurses, physicians, podiatrists, physical therapists, dietitians and others who manage skin and wound care patients across the continuum of health care are expected to attend. For more information on the symposium, please go to

The posters will be on display throughout the duration of the clinical symposium. Additional information can be obtained by calling Derma Sciences' customer service, at 800 445 7627.

About Derma Sciences

Derma Sciences is a global manufacturer and marketer of advanced wound-care products. Its key product, MEDIHONEY, is sold throughout the world by Derma Sciences and Comvita New Zealand -- the licensor of the patented honey-based technology -- and is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of wounds and burns, and was recently the focus of a positive large-scale randomized controlled trial on leg ulcers. Derma has two products in development: the BIOGUARD(TM) line of barrier gauze dressings, and DSC127, the company's novel angiotensin analog for accelerated wound healing and scar reduction. The barrier technology was licensed from Quick-Med in Q1 of 2007 and is pending its initial FDA marketing clearance. DSC127 was licensed from The University of Southern California in Q4 of 2007 and is entering into a Phase II study, with anticipated initial patient enrollment to begin in Q3 of 2008. For more information about Derma Sciences, Inc., visit its home page on the Internet at

Contact: Derma Sciences, Inc. Allen & Caron Inc

Edward J. Quilty Rudy Barrio (US Investors)

Chairman and CEO

(609) 514-4744 Brian Kennedy (media)

(212) 691-8087

SOURCE Derma Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
2. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
3. AGI Dermatics President to be Keynote Speaker at the 11th Annual Sunscreen Symposium
4. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
5. Government Expands Trial With IMVAMUNE(R) Smallpox Vaccine in Persons With Atopic Dermatitis/Eczema
6. Ferndale and Foamix Enter Development of an Innovative Foam for the Treatment of Atopic Dermatitis
7. Phosphagenics Announces Successful Phase 1 Transdermal Oxycodone Clinical Trial Results
8. Derma Sciences Expands Direct Sales Force for Advanced Wound Care, Looks to Double Again in 2008
9. AGI Dermatics Clinical Data Identifies L-Ergothioneine as Part of Skins Natural Antioxidant System
10. Lucid Launches VivaNet(R) Telemedicine Server for Dermatology Applications
11. JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis
Post Your Comments:
(Date:9/19/2017)... , ... September 19, 2017 , ... ... largest group of funded early-stage tech companies. “Grit” author Angela Duckworth and her ... joining the ic@3401 community is Cooley, an international law firm with decades of ...
(Date:9/19/2017)... ... 2017 , ... The new and improved Oakton® pocket testers, from Cole-Parmer, stand ... with a new cap design that is versatile, functional and leakproof. They are ideal ... test water quality. , The Oakton pocket testers have many user-friendly and functional features. ...
(Date:9/19/2017)... , Sept. 19, 2017 ValGenesis Inc., ... (VLMS) is pleased to announce the strategic partnership with ... provide clients with validation services using the latest technology ... VTI will provide clients with efficient and cost-effective validation ... marketing partner for the ValGenesis VLMS system. ...
(Date:9/19/2017)... ... 2017 , ... Molecular Devices, LLC, a leader in protein ... the CloneSelect™ Single-Cell Printer™ in North America. This novel system utilizes sophisticated ... documentation of monoclonality for use in cell line development. , Clonal cell ...
Breaking Biology Technology:
(Date:3/27/2017)... March 27, 2017  Catholic Health Services (CHS) ... Systems Society (HIMSS) Analytics for achieving Stage 6 ... sm . In addition, CHS previously earned a ... using an electronic medical record (EMR). ... level of EMR usage in an outpatient setting.  ...
(Date:3/23/2017)... PUNE, India , March 23, 2017 The report ... Equipment, Touchless Biometric), Industry, and Geography - Global Forecast to 2022", published by ... growing at a CAGR of 29.63% between 2017 and 2022. ... ... Logo ...
(Date:3/22/2017)... 2017 Optimove , provider of ... such as 1-800-Flowers and AdoreMe, today announced two ... Replenishment. Using Optimove,s machine learning algorithms, these features ... replenishment recommendations to their customers based not just ... customer intent drawn from a complex web of ...
Breaking Biology News(10 mins):